Analyzing GRI Bio (NASDAQ:GRI) & Immuneering (NASDAQ:IMRX)

GRI Bio (NASDAQ:GRI) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Analyst Ratings

This is a breakdown of current recommendations for GRI Bio and Immuneering, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1	0	2	0	2.33
Immuneering	1	0	5	1	2.86

GRI Bio presently has a consensus target price of $644.00, indicating a potential upside of 22,417.48%. Immuneering has a consensus target price of $16.50, indicating a potential upside of 242.32%. Given GRI Bio’s higher probable upside, research analysts plainly believe GRI Bio is more favorable than Immuneering.

Risk & Volatility

GRI Bio has a beta of -1.4, meaning that its share price is 240% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Earnings and Valuation

This table compares GRI Bio and Immuneering”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96 million	($8.39)	-0.34
Immuneering	N/A	N/A	-$61.04 million	($1.78)	-2.71

Immuneering is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares GRI Bio and Immuneering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-426.23%	-222.24%
Immuneering	N/A	-73.49%	-65.01%

Summary

Immuneering beats GRI Bio on 9 of the 12 factors compared between the two stocks.

About GRI Bio

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.